Back to News
Technology
Nov 22, 20265 views2 min read

Isomorphic Labs Raises 5 Billion Dollars in Series C to Accelerate AI Drug Discovery

Isomorphic Labs, the AI drug discovery company spun out of Google DeepMind, raised $5 billion in a Series C funding round this week. The company, led by DeepMind co-founder Demis Hassabis, uses AI to design new drug molecules and predict how they will interact with biological targets. The funding will be used to expand its pipeline of drug candidates and scale its research operations.

Isomorphic Labs Raises 5 Billion Dollars in Series C to Accelerate AI Drug Discovery

Isomorphic Labs raised $5 billion in a Series C funding round this week, one of the largest single fundraises in the history of biotechnology and AI.

The company, spun out of Google DeepMind in 2021, uses artificial intelligence to design new drug molecules and predict how they interact with biological targets. Its technology builds on AlphaFold, the AI system that solved the protein structure prediction problem and earned DeepMind's researchers a share of the 2024 Nobel Prize in Chemistry.

Demis Hassabis, who co-founded DeepMind and serves as CEO of Isomorphic Labs, announced the funding on social media. He said the capital will be used to expand the company's pipeline of drug candidates and scale its research operations globally.

Isomorphic Labs has partnerships with several major pharmaceutical companies, including Eli Lilly and Novartis, which have paid hundreds of millions of dollars to access its AI drug design platform.

The company's approach differs from traditional drug discovery, which relies heavily on trial-and-error laboratory experiments. Isomorphic Labs uses AI to predict which molecular structures are most likely to bind to disease targets and have favorable safety profiles, potentially cutting years off the drug development timeline.

The $5 billion raise values Isomorphic Labs at a figure that has not been publicly disclosed, but analysts estimate the company's valuation has grown significantly since its last funding round.

The investment comes as AI drug discovery has attracted intense interest from venture capital and pharmaceutical companies. Several other AI-focused biotech firms have raised large rounds in 2026, reflecting confidence that AI will reshape how new medicines are found and developed.